Dexasone

MALT Lymphoma

Izidore Lossos, MDSmall moleculePhase 2Active

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 89/ 100

Competitive context

32 Active assets in the MALT Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide SWOG Cancer Research Network	Phase 2	BBB
Rituximab City of Hope Medical Center	Phase 3	BBB
Vincristine Sulfate SWOG Cancer Research Network	Phase 2	BB
Fludarabine UNC Lineberger Comprehensive Cancer Center	Phase 2	BB
Etoposide Fred Hutchinson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Dexasone is also rated in:

chemotherapy-induced toxicityActive

A

Indicative · Phase 4

82 / 100

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.